Overview

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Aaron Chen
Collaborators:
Johns Hopkins University
Thrasher Research Fund
Treatments:
Cephalexin
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Criteria
Inclusion Criteria:

- Children between the ages of 6 months and 18 years of age (inclusive)

- Suspected purulent staphylococcal skin or soft tissue infection

- No hospitalization within the previous 14 days

- Must have reliable means of follow-up contact (e.g. working phone)

- Outpatient management in the judgement of treating physician

Exclusion Criteria:

- Hospitalization on initial visit

- Voluntary withdrawal by the treating physician in order to dictate the antibiotic
being used

- Patients with a history of hypersensitivity to or intolerance of cephalexin (or other
beta lactams) or clindamycin.

- Patients with altered immunity (inherited or acquired)

- Patients with skin infections related to surgical wounds or hardware.

- Patients currently on antibiotic therapy